Daraxonrasib received FDA orphan drug designation for pancreatic cancer, targeting RAS mutations in pancreatic ductal ...

A new analysis reveals unique symptom burdens and quality of life challenges in younger patients with neuroendocrine tumors, ...

Fast track designation allows Alphamab Oncology to interact with the FDA for guidance, potentially expediting approval ...

These cases illustrate scenarios where final pathology often reveals a higher risk of recurrence than anticipated, requiring ...

Marshall emphasizes the complexity of staying updated with various cancers and treatments, the diverse knowledge bases among event participants, and the importance of understanding data application ...

Nirogacestat significantly improved progression-free survival and objective response rates in desmoid tumor patients compared ...

As the incidence of obesity continues to rise nationally and globally, a new observational study published in Cancer reports ...

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

Early-onset NETs are rising, especially among racial minorities, with significant sociodemographic shifts observed in younger patients. Younger NET patients experience a higher symptom burden, ...

Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma. Non-clear cell renal cell carcinoma (nccRCC) is a less common disease state than ...

ITM-11 significantly improved PFS and OS in GEP-NET patients compared to everolimus, with a favorable safety profile and higher overall response rates. Dosimetry data showed targeted tumor uptake with ...

The ALPHAMEDIX-02 trial assessed 212Pb-DOTAMTATE in PRRT-naïve and PRRT-exposed GEP-NET patients, showing promising efficacy in both cohorts. PRRT-naïve patients exhibited a 60% response rate, while ...